Skip to main content

NewAmsterdam Pharma Company N.V.

corporate_fare Company Profile

NewAmsterdam Pharma Company N.V.

NAMS·NASDAQ·Life Sciences·CIK 0001936258

NewAmsterdam Pharma Co N.V. is a late-stage biopharmaceutical company focused on improving patient care for cardiometabolic diseases where current therapies are insufficient or not well tolerated. The company aims to address the need for a safe, well-tolerated, and convenient therapy to lower low-density lipoprotein cholesterol (LDL-C). Its primary product candidate is obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein (CETP) inhibitor. NewAmsterdam Pharma is developing obicetrapib, both alone and as a fixed-dose combination (FDC) with ezetimibe, as an adjunct to statin therapy for patients at risk of cardiovascular disease (CVD) with elevated LDL-C, for whom existing treatments are not effective enough or well tolerated. The company also believes that CETP inhibition might help mitigate the risk of developing other diseases, such as Alzheimer's disease. In its Phase 3 clinical trials, BROADWAY and BROOKLYN, obicetrapib as an adjunct to high-intensity statin therapy met its primary and secondary endpoints, showing statistically significant reductions in LDL-C. In the Phase 3 TANDEM clinical trial, obicetrapib combined with ezetimibe as an adjunct to high-intensity statin therapy also met its primary and secondary endpoints, with statistically significant reductions in LDL-C. Statistically significant LDL-C lowering was also observed in five Phase 2 clinical trials: TULIP, ROSE, OCEAN, ROSE2, and a Japan Phase 2b clinical trial, where obicetrapib was evaluated as a monotherapy or in combination with ezetimibe 10 mg. In these trials, side effects, including muscle-related side effects and drug-related treatment-emergent serious adverse events (TESAEs), were similar in frequency and severity to placebo.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for NAMS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Affiliate Files Intent to Sell $27.1M in Shares from Option Exercise
  • NewAmsterdam Pharma Reports Reduced Net Loss, Strong Cash Position, and Advances Obicetrapib Towards EU Approval and Alzheimer's Trial
  • NewAmsterdam Pharma Reports Strong 2025 Financials, Advances Obicetrapib Towards European Approval & Expands Pipeline
  • NewAmsterdam Pharma Reports $729M Cash, Funds Operations Through PREVAIL CVOT Readout and US Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$22.5M
Net Income
-$203.82M
Diluted EPS
-$1.72
Op. Cash Flow
-$147.78M
Free Cash Flow
-$148.03M
Operating Income
-$225.68M
Cash & Equivalents
$490M
Debt / Equity
0.00×
Net Margin
-9.06×
Shares Outstanding
114.4M sh
Source: 10-K · filed 2026-02-18 · accession 0001193125-26-056029
$18.32 -0.49% today
52-week range · as of 2026-11-04 $18.32 – $42.2
Market cap
$2.21B
Volume
1.7M (1.0× avg)
3-mo avg 1.7M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NAMS - Filings & News (Page 2)

NAMS
Feb 24, 2026, 4:22 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $36.01
Real-time Price: $18.32 info
Change: -$17.69 (-49%) info
Market Cap: $2.208B info
NAMS
Feb 18, 2026, 7:00 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $34.74
Real-time Price: $18.32 info
Change: -$16.42 (-47%) info
Market Cap: $2.208B info
NAMS
Feb 18, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.35
Real-time Price: $18.32 info
Change: -$17.03 (-48%) info
Market Cap: $2.208B info
NAMS
Jan 09, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.73
Real-time Price: $18.32 info
Change: -$17.41 (-49%) info
Market Cap: $2.208B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets